Background
Follicular lymphoma biology and disease pathogenesis
Relapsed/refractory follicular lymphoma-approved and investigational approaches
Immunomodulators
Small molecule inhibitors
PI3K inhibitors
Treatment | Target specificity | Publication/NCT# | Phase | Total n [FL] | Median lines of prior therapy | ORR%a [CR%] | Median PFS (mos) | Grade ≥ 3 AEs (%)b | Approved |
---|---|---|---|---|---|---|---|---|---|
Single agent studies | |||||||||
Idelalisib | δ | [36] | II | 125 [72] | 4 | 45 [3] | 11 | + | |
Copanlisib | α/δ | II | 142 [104] | 3 | 59 [20] | 12.5 | + | ||
Duvelisib | δ/γ | [41] | II | 129 [83] | 3 | 42 [1] | 9.5 | + | |
Umbralisib | δ, CK1ε | [44] | II | 208 [117] | 2 | 45 [5] | 10.6 | + | |
Parsaclisib | δ | NCT03126019 | II | NAc | NAc | NAc | NAc | NAc | – |
Zandelisib | δ | NCT03768505 | II | NAc | NAc | NAc | NAc | NAc | – |
YY-20394 | δ | NCT04370405 | II | NAc | NAc | NAc | NAc | NAc | – |
Tenalisib | δ/γ | NCT03711578 | II | NAc | NAc | NAc | NAc | NAc | – |
Combination studies | |||||||||
Duvelisib + BR or R | δ/γ | [50] | I | 46 [15] | 2 | Duvelisib + R: 62 [19], Duvelisib + BR: 58 [17]d | Duvelisib + R: 10.7, Duvelisib + BR: 5.3d | – | |
Umbralisib + ublituximab | δ, CK1ε | [51] | I | 75 [19] | 3 | 44 [22] | NP | – | |
Copanlisib + BR or R-CHOP | α/δ | NCT03711578 | III | NAc | NAc | NAc | NAc | NAc | – |
Duvelisib + nivolumab | δ/γ | NCT03892044 | I | NAc | NAc | NAc | NAc | NAc | – |
Idelalisib + pembrolizumab | δ | NCT02332980 | II | NAc | NAc | NAc | NAc | NAc | – |
Duvelisib + acalabrutinib | δ/γ | NCT04836832 | I/II | NAc | NAc | NAc | NAc | NAc | – |
Umbralisib + pembrolizumab | δ, CK1ε | NCT03283137 | I | NAc | NAc | NAc | NAc | NAc | – |
Umbralisib + ublituximab + lenalidomide | δ, CK1ε | NCT04635683 | I | NAc | NAc | NAc | NAc | NAc | – |
Approved PI3Ki
Emerging PI3Ki
Combinatorial approaches incorporating PI3Ki
Epigenetic therapies
Treatment | Target | Publication/NCT# | Phase | Total n [FL] | Median lines of prior therapy | ORR%a [CR%] | Median PFS (mos) | Grade ≥ 3 AEs (%)b | Approved |
---|---|---|---|---|---|---|---|---|---|
EZH2 inhibitors | |||||||||
Tazemetostat | EZH2 | [60] | II | 99 [99; MT 45, WT 45) | 2 | MT: 69 [13] WT: 35 [4] | MT: 13.8 WT: 11.1 | Nonec | + |
Tazemetostat + rituximab | EZH2 | NCT04762160 | II | NAd | NAd | NAd | NAd | NAd | – |
Tazemetostat + lenalidomide + rituximab | EZH2 | NCT04224493 | I | NAd | NAd | NAd | NAd | NAd | – |
HDAC inhibitors | |||||||||
Vorinostat | Class 1 and 2 HDACs | [62] | II | 50 [39] | 1 | 49 [10] | 20 | – | |
Vorinostat + rituximab | Class 1 and 2 HDACs | [64] | II | 28 [22] | 2 | 41 [27] | 18.8 | – | |
Mocetinostat | HDAC 1,2,3,11 | [66] | II | 72 [31] | 4 | 11 [4] | 26.3 | – | |
DNMT inhibitors | |||||||||
5-azacytidine + R-CHOP | DNMT1 | [68] | I | 10 [3] | 3 | 66 [33] | NP | – | |
PRMT inhibitors | |||||||||
GSK3326595 | PRMT5 | NCT02783300e | I | NAd | NAd | NAd | NAd | NAd | – |
JNJ-64619178 | PRMT5 | NCT03573310e | I | NAd | NAd | NAd | NAd | NAd | – |
BET inhibitors | |||||||||
CPI-0610 | BRD2, BRD4 | [74] | I | 44 [8] | 4 | 12 [0] | NP | NP | – |
EZH2 inhibitors
Histone deacetylase inhibitors (HDACi)
Inhibitors of DNA methyltransferases (DNMT inhibitors)
Inhibitors of Protein arginine methyltransferases (PRMT inhibitors)
Inhibitors of Bromodomain and Extraterminal Motif (BET) proteins
Combinatorial approaches using epigenetic therapies
BCL2 inhibitors
BCR pathway inhibitors
Antibodies and antibody–drug conjugates (ADCs)
Checkpoint blockade
Cellular therapies
Chimeric antigen receptor T cell (CART) therapy
Axicabtagene ciloleucel
Tisagenlecleucel
Bispecific T cell engager (BiTe) antibody therapy
BiTe | NCT#/publication | Route/Administration schedule | Phase | Total n [FL] | Median lines of prior therapy | % POD24 | ORR%a [CR%] | mPFS | CRS % [G ≥ 3] | Neuro % [G ≥ 3] | Approved |
---|---|---|---|---|---|---|---|---|---|---|---|
Mosunetuzumab | [96] | IV Qweekly for cycle 1, Q21 days for cycles ≥ 2, stopped after cycle 8 for CR | 1 | 62 [62] | 3 | 48 | 68 [50] | 11.8 | 2 | 0 | – |
Odronextumab | [97] | IV Qweekly for weeks 1–12, Q2 weeks for weeks 12–36 | 1 | 96 [25] | 3 | NP | 93 [71] | NP | 7 | 3 | – |
Odronextumab | NCT03888105 [98] | IV Qweekly for weeks 1–12, Q2 weeks for weeks 12–36 | II | NAb | NAb | NAb | NAb | NAb | NAb | NAb | – |
Epcoritamab | [100] | sq Qweekly C1-2, Q2 weeks C3-6, Q4 weeks thereafter, 28 day cycles | I | 67 [12] | 3 | NP | 100 [25] | NP | 0 | 3 | – |
Glofitamab | [108] | Obinutuzumab on D-7, weekly for two weeks then Q2 weeks for 28 weeks | I | 171 [44] | 3 | NP | 62 [52]c | 11.8 | 3.5 | 1.2 | – |